cument 2750-47 Filed 06/17/24 Page 1 of 9

Case 1:19-md-02875-RMB-SAK Document 2750-47 PageID: 103361

Exhibit 59

缬沙坦残留溶剂未知峰研究报告 Study Report of Unknown Peak in Residual Solvent of Valsartan

文件编号 Document Number **QCC-18005**

版本号 Version 1

川南化验室 编写部门 Preparation Dept. Chuannan QC

川南化验室 保管部门 Archiving Dept. Chuannan QC



浙江华海药业股份有限公司 ZHEJENNO HUKHENI PHENTIMENCEUTICAL CO.,LTD.

题目:缬沙坦残留溶剂未知峰研究报告 文件编号:QCC-18005
Study Report of Unknown Peak in Residual
Solvent of Valsartan 版本号 Version: 1

文件变更历史

Document Change History

版本号	生效日期	主要变更描述
Version No.	Effective Date	Summary of Changes from Previous Version
1	70/8.05.3	本文件为新订/Newly drafted

浙江华海药业股份有限公司 ZHEJIKNO HUKHKI PHKIRMICGEUTICKL CO.,LTD.

文件编号: QCC-18005 题目: 缬沙坦残留溶剂未知峰研究报告 Unknown Peak Study Report of Residual Document no.: QCC-18005 Solvent for Valsartan 版本号 Version: 1

报告审批表

Document 2750-47 PageID: 103364

Review and Approval for Report

	renew and rep		and the same of th
	姓名/职务	现他	全国的工
Dept.	Name & Title	Role -	Signature & Date
川南化验室 Chuannan QC	王俊/高级主管 Wangjun/ Senior Supervisor	编写报告 Prepare report	10/8.05.30 Wang Jan 20/8.05.30
川南化验室 Chuannan QC	唐银华/分析总监助理 Tang Yinhua/ Assistant of QC Director	审核 正确性和完整性 Review accuracy and completeness	Tonfline 2013.
川南技术部 Tech. Dept. of Chuannan Site	董鹏/技术副总监 Dong Peng/ Vice Director of Tech.	审核 正确性和完整性 Review accuracy and completeness	Dung Peng 2018.05.30
原料药质量研 究部 API QR	陈文斌/分析总监 Chen Wenbin/ Analytical Director	审核 正确性和完整性 Review accuracy and completeness	2018.05.31 Chen Wendin 2018.05.3
质量管理部 QA	胡跃林/质量总监助理 Hu Yuelin/Assistant of QA Director	批准 与 cGMP 的符合性 Approve	topset & 8-4-3



题目:缬沙坦残留溶剂未知峰研究报告 Unknown Peak Study Report of Residual Solvent for Valsartan 文件编号: QCC-18005

Document no.: QCC-18005

版本号 Version: 1

Page 1 of 23

目 录/Contents

	研究背景 Backgroud
	研究目的 Purpose
Ξ,	研究内容 Content
	3.1 Unknown peak_1 (RT=3.5min): Dimethyl sulfide
	3.2 Unknown peak_2 (RT=4.1min): Dichloromethane
	3.3 Unknown peak_3 (RT=4.5min):MTBE
	3.4 Unknown peak_4 (RT=4.9min): Isobutyraldehyde
	3.5 Unknown peak_5 (RT=5.0min); n-hexane
	3.6 Unknown peak_6 (RT=7.4min):
	3.7_Unknown peak_7 (RT=9.8min): Isopropyl acetate; Unknown peak_8 (RT=12.0min)
	Ethyl Propionate; Unknown peak_9 (RT=12.2min): Propyl acetate
四、	对未知峰的控制要求 Control requirement of unknown peak
五、	风险评估 Risk assessment
六.	研究结论 Conclusion 23

题目: 缬沙坦残留溶剂未知峰研究报告	文件编号:	QCC-18005
Study Report of Unknown Peak in Residual	Document no.: QCC-18005	
Solvent of Valsartan	版本号 Version: 1	Page 2 of 23

Document 2750-47

PageID: 103366

一、研究背景/Backgroud

华海药业缬沙坦残留溶剂(甲醇、乙醇、乙酸乙酯、甲苯)检测方法(华海方法详见附件1)项下发现存在多个未知峰,典型图谱如图1。由图1可知,此次研究涉及的未知峰共计9个,并根据出峰时间依次命名为未知峰_1~未知峰_9(未知峰出峰情况表1)。

Many unknown peaks are identified when tested residual solvent (methonal, ethanol, ethyl acetate, toluene) of Valsartan with Huahai method (For Huahai Analytical method, please refer to Attachment 1), refer to Figure 1 for typical chromatogram. As indicated in Figure 1, there are 9 unknown peaks involved in this study. In the order of their retention time, these peaks are named as unknown peak_1 to unknown peak_9 respectively. (For RT of unknown peaks, please refer to Figure 1).




图 1 (华海方法典型图谱)

Figure 1 Typical chromatogram of Huahai method

未知峰情况 Unknown peaks	RT (min)	RRT(相对于乙酸乙酯) RRT (relative RT to ethyl acctate)
未知峰_1 Unknown peak_1	3.5	0.51
未知峰_2 Unknown peak_2	4.1	0.59
未知峰_3 Unknown peak_3	4.5	0.65
未知峰_4 Unknown peak_4	4.9	0.71

题目:缬沙坦残留溶剂未知峰研究报告 Study Report of Unknown Peak in Residual	文件编号: QCC-18005 Document no.: QCC-18005	
Solvent of Valsartan		
	版本号 Version: 1	Page 3 of 23

Document 2750-47

PageID: 103367

未知峰_5 Unknown peak_5	5.0	0.72
未知峰_6 Unknown peak_6	7.4	1.07
未知峰_7 Unknown peak_7	9.8	1.42
未知峰_8 Unknown peak_8	12.0	1.74
未知峰_9 Unknown peak_9	12.2	1.77

表1(未知峰出峰情况)

Table 1 RT of each unknown peak

同时诺华客户反馈采用诺华方法(诺华方法详见附件2)检测缬沙坦残留溶剂,其图 谱也存在若干未知峰,典型图谱如图 2:

Feedback was aslo received from Novartis that when testing residual solvent of Valsartan with Novartis method (Please refer to Attachment 2 for Novartis method), some unknown peaks were also identified. For Typical chromatogram, please refer to Figure 2.




Figure 2 Typical chromatogram of Novartis method

基于华海以往对未知溶剂峰的部分研究,结合诺华本次反馈后的持续研究,并根据 ICH 法规及诺华客户的要求,对此次研究涉及未知峰进行总体评估。

Document 2750-47 PageID: 103368

加工华海药业股份有限公司 ZHEJIKANG HUKUHAN PHIKAMING EUTHCAL CO.,LTD.

题目:缬沙坦残留溶剂未知峰研究报告 Study Report of Unknown Peak in Residual Solvent of Valsartan 文件编号: QCC-18005

Document no.: QCC-18005

版本号 Version: 1

Page 4 of 23

Based on the huahai's histotical study of unknown solvent peak as well as the study continued after receiving the feedback from Novartis, an overrall assessment regarding unknown peaks involved in this study is performed as per ICH as well as Novartis requirement.

二、研究目的/Purpose

根据华海药业缬沙坦方法项下残留溶剂未知峰的出峰情况,对其进行鉴别,寻找其最可能的来源,并对这些溶剂进行定量,以评估其残留是否符合 ICH 法规和诺华客户的要求,以及其对产品质量的影响。

Identify unknown peaks (Huahai method) based on their RT, find the most probable source, quantify the solvent corresponding to each peak to see whether the residue comply with ICH and Novartis requirement, to evaluate the impact on product quality.


三、研究内容/Content

华海药业通过对缬沙坦 ROS (ROS 详见图 3)的分析,梳理工艺中涉及溶剂(工艺涉及溶剂详见表 2),并借用 GC-MS 解析、GC 定位等手段,对缬沙坦未知峰的鉴别、可能的来源以及定量分析进行研究。

Identify, quantify and find probable source of unknown peaks by analysis of ROS of Valsartan and solvents used in process (Please refer to Table 2 Solvents used in the process), by means of GC-MS and GC RT identification, etc..

Ros of Valsartan

Step 1: Synthesis of L-valine methyl ester hydrochloride



L-Valine C₅H₁₁N O₂ Mr: 117.1 Methanol CH₄O Mr: 32.0 L-valine methyl ester hydrochloride C₆H₁₄NO₂Cl Mr:167.6

Document 2750-47 PageID: 103369

沙斯工华海药业股份有限公司 ZHEJIKNG HURHKI PHRRMACEUTICAL CO.,LTD.

题目:缬沙坦残留溶剂未知峰研究报告 Study Report of Unknown Peak in Residual Solvent of Valsartan 文件编号: QCC-18005

Document no.: QCC-18005

版本号 Version: 1

Page 23 of 23

六、研究结论/Conclusion

综上研究所述,华海药业缬沙坦残留溶剂(甲醇、乙醇、乙酸乙酯、甲苯)检测存在的9个未知峰均已确认其来源或可能来源。其中2个未知峰(二甲基硫醚和未知峰_6)确定来源于分析方法,对产品质量无影响。另外7个未知峰中能够确定二氯甲烷来源于起始物料的工艺溶剂残留,MTBE来源于缬沙坦工艺溶剂,乙酸异丙酯、丙酸乙酯、乙酸丙酯来源于缬沙坦工艺溶剂乙酸乙酯,异丁醛和正己烷均未能明确其来源,但异丁醛找到了其最可能的反应机理,正己烷可能来源于溶剂的微量残留,通过定量分析,结果均远远低于指标,用甲苯 10% ICH 标准(89ppm)的峰面积对未知峰进行控制,对产品质量无影响。

From the above, 9 unknown peaks in residue solvents test method (methanol, ethanol, ethyl acetate and toluene) of Valsartan have been identified or the probable source identified. 2 unknown peaks (Dimethyl sulfide and unknown peak _6) are identified to be introduced by analytical method and there is no impact on product quality. For other 7 unknown peaks, the unknown peak of dichloromethane is introduced by residual process solvent of starting material; MTBE is process solvent of Valsartan; Isoproply acetate, Ethyl propionate and Propyl acetate are introduced by ethyl acetate (process solvent); the exact source of Isobutyraldehyde and N-hexane are not identified. However, the most probable reaction mechanism of Isobutyraldehyde has been identified. N-hexane may be introduced by trace residue of solvent. The results are far lower than the specification through quantitative analysis. The unknown peaks can be controlled by comparing to the peak area of 10% toluene, ICH limit (89ppm). The product quality is less likely to be impacted.